Generic Product News (October 2018)

MARKETED BY: Teva Pharmaceutical Industries Ltd

COMPARE TO: Uceris

INDICATION: Teva Pharmaceutical Industries recently launched a generic equivalent of Uceris extended-release tablets in the United States. The

drug is a glucocorticosteroid indicated to alleviate the symptoms of active ulcerative colitis and induce remission. The most common symptoms of

the chronic inflammatory bowel disease are intermittent rectal bleeding, abdominal pain, and diarrhea. Budesondine is available in 9-mg tablets and can be prescribed to adults with mild to moderate ulcerative colitis.

DOSAGE FORM: Tablets

FOR MORE INFORMATION: tevapharm.com/news

MARKETED BY: Mylan N.V.

COMPARE TO: Angiomax

INDICATION: Mylan is launching Bivalirudin for injection, a thrombin inhibitor that can be used as an anticoagulant. The injection is generically equivalent to The Medicines Company’s Angiomax. Bivalirudin can be used as an anticoagulant in patients with angina who are undergoing percutaneous transluminal coronary angioplasty. It can also be used to treat patients undergoing a similar procedure, percutaneous coronary intervention, who are either using glycoprotein IIb/IIIa inhibitors or have heparin-induced thrombocytopenia with or without thrombosis syndrome. Patients should receive bivalirudin with aspirin.

DOSAGE FORM: Injection

FOR MORE INFORMATION: mylan.com

GENERIC POTASSIUM CHLORIDE ORAL SOLUTION

MARKETED BY: Amneal

COMPARE TO: Potassium Chloride

INDICATION: Amneal has received FDA approval for its generic version of potassium chloride oral solution, a mineral supplement to prevent or treat hypokalemia. Potassium is essential for the function of nerve cells and the muscle cells of the heart, but certain medications, as well as a prolonged illness with diarrhea or vomiting, can deplete its levels. Amneal notes that a majority of patients who receive potassium chloride supplementation are in an institutional and long-term-care setting, where oral solutions may be necessary or preferred.

DOSAGE FORM: Oral solution

FOR MORE INFORMATION: Amneal.com

TEMSIROLIMUS INJECTIONMARKETED BY: Accord Healthcare Inc

COMPARE TO: Torisel

INDICATION: FDA officials have approved temsirolimus as an AP-rated generic equivalent to Torisel to

treat advanced renal cell carcinoma. Temsirolimus works by inhibiting the mTOR protein that plays a role in the growth and division of healthy cells and kidney cancer cells.

DOSAGE FORM: Intravenous solution

FOR MORE INFORMATION: accord-healthcare.com